By Tom Murphy

CVS Health is pulling from its shelves some cough-and-cold treatments that contain an ingredient that has been deemed ineffective by doctors and researchers.

The drug store chain said it will remove a small number of oral decongestants that contain phenylephrine as the only active ingredient. CVS also said it will still sell “many other oral cough and cold products to meet consumer needs.”

A company spokeswoman declined to elaborate on how many products will be removed when contacted by The Associated Press Friday morning.

CVS Health runs more than 9,000 stores in the United States. Representatives of its national rival, Walgreens, has not pulled any products.

A Walgreens spokeswoman said the company is monitoring the situation and partnering with its clinical integrity office and suppliers “on appropriate next steps.”

U.S. Food and Drug Administration advisers voted unanimously last month against the effectiveness of phenylephrine, which is found in popular versions of Sudafed, Dayquil and other medications stocked on store shelves.

The FDA had asked its outside advisers to examine the long-questioned drug ingredient. Studies conducted in the past few years by the drugmakers Merck and Johnson & Johnson have shown no difference between phenylephrine medications and placebos for relieving congestion.

The FDA, which has not acted on the recommendation of its advisers, said the drug appears more effective when applied directly to the nose, in sprays or drops. Those products are not under review.

Phenylephrine had become the main drug in over-the-counter decongestants when medicines with an older ingredient — pseudoephedrine — were moved behind pharmacy counters. A 2006 law had forced the move because pseudoephedrine can be illegally processed into methamphetamine.

Those original versions of Sudafed and other medicines remain available without a prescription.

The CVS Health announcement comes shortly before another cold-and-flu season starts in the United States as winter sets in. Last year, an unusually fast start to the season led to shortages of Children’s Tylenol and other medications customers can purchase over-the-counter, or without a prescription.

Share:
More In Business
Trump says Netflix deal to buy Warner Bros. ‘could be a problem’ because of size of market share
President Donald Trump says a deal struck by Netflix last week to buy Warner Bros. Discovery “could be a problem” because of the size of the combined market share. The Republican president says he will be involved in the decision about whether federal regulators should approve the deal. Trump commented Sunday when he was asked about the deal as he walked the red carpet at the Kennedy Center Honors. The $72 billion deal would bring together two of the biggest players in television and film and potentially reshape the entertainment industry.
What to know about changes to Disney parks’ disability policies
Disney's changes to a program for disabled visitors are facing challenges in federal court and through a shareholder proposal. The Disability Access Service program, which allows disabled visitors to skip long lines, was overhauled last year. Disney now mostly limits the program to those with developmental disabilities like autism who have difficulty waiting in lines. The changes have sparked criticism from some disability advocates. A shareholder proposal submitted by disability advocates calls for an independent review of Disney's disability policies. Disney plans to block this proposal, claiming it's misleading. It's the latest struggle by Disney to accommodate disabled visitors while stopping past abuses by some theme park guests.
Load More